FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jan-Willem Koten

Research Profile

Chemicals & Drugs

Disorders

Living Beings

Physiology

Mutation

Procedures

Genes & Molecular Sequences

Oncogenes

Concepts & Ideas

Geographic Areas

Netherlands

Co-author Network

Publications

TOP 3
Paul G P M Ziekman; Jolle Kirpensteijn; Jan-Willem Koten; Willem D E N Otter; Jurgen F V Tan; Erik Teske; John J L Jacobs
Intratumoural interleukin-2 therapy can induce regression of non-resectable mastocytoma in dogs.
Daan J der Kinderen; Ben C V M Disselhoff; Jan-Willem Koten; Peter C de Bruin; Cees A Seldenrijk; Frans L Moll
Histopathologic studies of the below-the-knee great saphenous vein after endovenous laser ablation.
Jan-Willem Koten; Guilherme Wood; Peter Hagoort; Rainer Goebel; Peter Propping; Klaus Willmes; Dorret I Boomsma
Genetic contribution to variation in cognitive function: an FMRI study in twins.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jan-Willem Koten (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Paul G P M Ziekman; Jolle Kirpensteijn; Jan-Willem Koten; Willem D E N Otter; Jurgen F V Tan; Erik Teske; John J L Jacobs
Intratumoural interleukin-2 therapy can induce regression of non-resectable mastocytoma in dogs.
Anticancer research 2013;33(1):161-5.
2009: Daan J der Kinderen; Ben C V M Disselhoff; Jan-Willem Koten; Peter C de Bruin; Cees A Seldenrijk; Frans L Moll
Histopathologic studies of the below-the-knee great saphenous vein after endovenous laser ablation.
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2009;35(12):1985-8.
2009: Jan-Willem Koten; Guilherme Wood; Peter Hagoort; Rainer Goebel; Peter Propping; Klaus Willmes; Dorret I Boomsma
Genetic contribution to variation in cognitive function: an FMRI study in twins.
Science (New York, N.Y.) 2009;323(5922):1737-40.
2008: Willem Den Otter; john jacobs; Jan J Battermann; Gerrit Jan Hordijk; Zachary Krastev; Ekaterina V Moiseeva; Rachel J E Stewart; Paul G P M Ziekman; Jan-Willem Koten
Local therapy of cancer with free IL-2.
Cancer immunology, immunotherapy : CII 2008;57(7):931-50.
2006: R J E Stewart; F W G Hill; Agnieszka Masztalerz; john jacobs; Jan-Willem Koten; Willem Den Otter
Treatment of ocular squamous cell carcinomas in cattle with interleukin-2.
The Veterinary record 2006;159(20):668-72.
2005: Zachary Krastev; V Koltchakov; R Tomova; S Deredjian; A Alexiev; D Popov; B Tomov; Jan-Willem Koten; john jacobs; Willem Den Otter
Locoregional IL-2 low dose applications for gastrointestinal tumors.
World journal of gastroenterology : WJG 2005;11(35):5525-9.
2005: john jacobs; Gerrit Jan Hordijk; Ina M Jürgenliemk-Schulz; Chris H J Terhaard; Jan-Willem Koten; Jan J Battermann; Willem Den Otter
Treatment of stage III-IV nasopharyngeal carcinomas by external beam irradiation and local low doses of IL-2.
Cancer immunology, immunotherapy : CII 2005;54(8):792-8.
2004: Halina Kusnierczyk; Elzbieta Pajtasz-Piasecka; Jan-Willem Koten; Caspaar Bijleveld; Krzysztof Krawczyk; Willem Den Otter
Further development of local IL-2 therapy of cancer: multiple versus single IL-2 treatment of transplanted murine colon carcinoma.
Cancer immunology, immunotherapy : CII 2004;53(5):445-52.
2004: Gert Bos; john jacobs; Jan-Willem Koten; Sophie R Van Tomme; Theo F J Veldhuis; Cornelus F van Nostrum; Willem Den Otter; Wim E Hennink
In situ crosslinked biodegradable hydrogels loaded with IL-2 are effective tools for local IL-2 therapy.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2004;21(4):561-7.
2003: Jan-Willem Koten; Marja J A van Luyn; Jenny A Cadée; Linda A Brouwer; Wim E Hennink; C Bijleveld; Willem Den Otter
IL-2 loaded dextran microspheres with attractive histocompatibility properties for local IL-2 cancer therapy.
Cytokine 2003;24(3):57-66.
2003: Zachary Krastev; V Koltchakov; D Popov; A Alexiev; Jan-Willem Koten; Willem Den Otter
A case of hepatocellular carcinoma (HCC): treatment with local application of alcohol and interleukin 2 (IL-2).
Hepato-gastroenterology 2003;50(53):1647-9.
2003: Ekaterina Moiseeva; Irina B Merkulova; Caspaar Bijleveld; Jan-Willem Koten; Anatoly I Miroshnikov; Willem Den Otter
Therapeutic effect of a single peritumoural dose of IL-2 on transplanted murine breast cancer.
Cancer immunology, immunotherapy : CII 2003;52(8):487-96.
2003: Zachary Krastev; V Koltchakov; B Tomov; Jan-Willem Koten
Non-melanoma and non-renal cell carcinoma malignancies treated with interleukin-2.
Hepato-gastroenterology 2003;50(52):1006-16.
2003: T J P Spoormakers; Wim R Klein; john jacobs; Th S G A M Van Den Ingh; Jan-Willem Koten; Willem Den Otter
Comparison of the efficacy of local treatment of equine sarcoids with IL-2 or cisplatin/IL-2.
Cancer immunology, immunotherapy : CII 2003;52(3):179-84.
2002: Anton H C Baselmans; Jan-Willem Koten; Jan J Battermann; Jaap E Van Dijk; Willem Den Otter
The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy.
Cancer immunology, immunotherapy : CII 2002;51(9):492-8.
2002: Annette C Moll; Saskia M Imhof; Lex Bouter; Willem Den Otter; Jan-Willem Koten
An infant with Down syndrome and retinoblastoma. A possible non-fortuitous association.
Ophthalmic genetics 2002;23(2):135-6.
2002: Cornelis J De Groot; Jenny A Cadée; Jan-Willem Koten; Wim E Hennink; Willem Den Otter
Therapeutic efficacy of IL-2-loaded hydrogels in a mouse tumor model.
International journal of cancer. Journal international du cancer 2002;98(1):134-40.
2001: Zachary Krastev; V Koltchakov; N Vladov; D Popov; A Milev; Jan-Willem Koten; Willem Den Otter
A mesothelioma that is sensitive to locally applied IL-2.
Cancer immunology, immunotherapy : CII 2001;50(4):226-7.
2000: Robert J J van Es; A H Baselmans; Jan-Willem Koten; Jaap E Van Dijk; Ron Koole; Willem Den Otter
Perilesional IL-2 treatment of a VX2 head-and-neck cancer model can induce a systemic anti-tumour activity.
Anticancer research 2000;20(6B):4163-70.
1999: Willem Den Otter; Jan-Willem Koten
A 4-mutation model of carcinogenesis for tumour suppressor genes.
Anticancer research 1999;19(6A):4845-52.
1999: Jan-Willem Koten; H Beukers; Willem Den Otter
History of cancer research in nosological perspective.
Anticancer research 1999;19(6A):4613-26.
1999: Willem Den Otter; R Root-Bernstein; Jan-Willem Koten
What is cancer? Theories on carcinogenesis.
Anticancer research 1999;19(6A):4601-2.
1999: Jan-Willem Koten; Willem Den Otter
Suggestion for IL-2 treatment of conjunctival squamous carcinoma.
The British journal of ophthalmology 1999;83(8):995-6.
1999: Willem Den Otter; L Balemans; Jan J Battermann; MR Bernsen; J A Cadee; Z Dobrowolski; Linda A Everse; Lucja Fiszer-Maliszewska; R Gavhumende; J W De Groot; K De Groot; Wim E Hennink; F W G Hill; I Jurgenliemp-Schulz; Wim R Klein; Jan-Willem Koten; R A Maas; Peter A Steerenberg; R Stewart; M Zembala
Local low-dose IL-2 therapy.
Hepato-gastroenterology 1999;46 Suppl 1():1280-6.
1999: MR Bernsen; J W Tang; Linda A Everse; Jan-Willem Koten; Willem Den Otter
Interleukin 2 (IL-2) therapy: potential advantages of locoregional versus systemic administration.
Cancer treatment reviews 1999;25(2):73-82.
1998: A W Brinkert; Annette C Moll; M J Jager; Willem Den Otter; Jan-Willem Koten; J A J Faber; KE Tan
Distribution of tumors in the retina in hereditary retinoblastoma patients.
Ophthalmic genetics 1998;19(2):63-7.
1998: Willem Den Otter; Z Dobrowolski; A Bugajski; B Papla; A P Van Der Meijden; Jan-Willem Koten; T A Boon; M Siedlar; M Zembala
Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients.
The Journal of urology 1998;159(4):1183-6.
1997: Annette C Moll; Saskia M Imhof; E M Bleeker-Wagemakers; Willem Den Otter; Lex Bouter; Jan-Willem Koten; KE Tan
Prevalence of mental retardation in patients with hereditary retinoblastoma.
Ophthalmic genetics 1997;18(4):217-20.
1997: Annette C Moll; Dirk J Kuik; Lex Bouter; Willem Den Otter; P Dick Bezemer; Jan-Willem Koten; Saskia M Imhof; B P Kuyt; KE Tan
Incidence and survival of retinoblastoma in The Netherlands: a register based study 1862-1995.
The British journal of ophthalmology 1997;81(7):559-62.
1996: Annette C Moll; Jan-Willem Koten; D A Lindenmayer; Linda A Everse; KE Tan; A Hamburg; J A J Faber; Willem Den Otter
Three histopathological types of retinoblastoma and their relation to heredity and age of enucleation.
Journal of medical genetics 1996;33(11):923-27.
1996: Willem Den Otter; T E Merchant; D Beijerinck; Jan-Willem Koten
Breast cancer induction due to mammographic screening in hereditarily affected women.
Anticancer research 1996;16(5B):3173-5.
1996: Annette C Moll; Saskia M Imhof; L M Bouter; Dirk J Kuik; Willem Den Otter; P Dick Bezemer; Jan-Willem Koten; KE Tan
Second primary tumors in patients with hereditary retinoblastoma: a register-based follow-up study, 1945-1994.
International journal of cancer. Journal international du cancer 1996;67(4):515-9.
1996: Annette C Moll; Saskia M Imhof; Dirk J Kuik; L M Bouter; Willem Den Otter; P Dick Bezemer; Jan-Willem Koten; KE Tan
High parental age is associated with sporadic hereditary retinoblastoma: the Dutch retinoblastoma register 1862-1994.
Human genetics 1996;98(1):109-12.
1995: Willem Den Otter; FW Hill; Wim R Klein; Linda A Everse; E J Ruitenberg; Leo T M van der Ven; Jan-Willem Koten; Peter A Steerenberg; J A J Faber; V P M G Rutten
Ocular squamous cell carcinoma in Simmental cattle in Zimbabwe.
American journal of veterinary research 1995;56(11):1440-4.
1995: Willem Den Otter; FW Hill; Wim R Klein; Jan-Willem Koten; Peter A Steerenberg; P H De Mulder; C Rhode; R Stewart; J A J Faber; E J Ruitenberg
Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up.
Cancer immunology, immunotherapy : CII 1995;41(1):10-4.
1994: FW Hill; V P M G Rutten; M H Hoyer; Wim R Klein; Jan-Willem Koten; P A Steerenberg; E J Ruitenberg; W Den Otter
Local bacillus Calmette-Guérin therapy for bovine vulval papilloma and carcinoma.
Cancer immunology, immunotherapy : CII 1994;39(1):49-52.
1994: FW Hill; Wim R Klein; M J Hoyer; V P M G Rutten; ND Kock; Jan-Willem Koten; P A Steerenberg; E J Ruitenberg; W Den Otter
Antitumor effect of locally injected low doses of recombinant human interleukin-2 in bovine vulval papilloma and carcinoma.
Veterinary immunology and immunopathology 1994;41(1-2):19-29.
1993: W Den Otter; FW Hill; Wim R Klein; Jan-Willem Koten; P A Steerenberg; P H De Mulder; V P M G Rutten; E J Ruitenberg
Low doses of interleukin-2 can cure large bovine ocular squamous cell carcinoma.
Anticancer research 1993;13(6B):2453-5.
1993: Jan-Willem Koten; J P Neijt; B A Zonnenberg; W Den Otter
The difference between benign and malignant tumours explained with the 4-mutation paradigm for carcinogenesis.
Anticancer research 1993;13(4):1179-82.
1993: Willem Den Otter; T E Merchant; D Beijerinck; Jan-Willem Koten
Exclusion from mammographic screening of women genetically predisposed to breast cancer will probably eliminate mammographically induced breast cancer.
Anticancer research 1993;13(4):1113-5.
1993: Willem Den Otter; Jan-Willem Koten; R A Maas; D J DerKinderen
Are atopic disorders due to a TH2 clone?
The British journal of dermatology 1993;128(1):102.
1993: R A Maas; Hub F J Dullens; D Henk; J Van Weering; H J De Mik; Jan-Willem Koten; R J Belger; Willem Den Otter
Histological analysis of IL-2 induced regression of murine solid SL2-tumors.
Biotherapy (Dordrecht, Netherlands) 1993;6(2):83-91.
1991: H J De Mik; Jan-Willem Koten; R A Maas; Hub F J Dullens; Willem Den Otter
Tumour regression by IL-2 mediated stagnation of blood flow.
In vivo (Athens, Greece) 1991;5(6):679-84.
1991: Willem Den Otter; R A Maas; Jan-Willem Koten; Hub F J Dullens; M Bernsen; Wim R Klein; V P M G Rutten; Peter A Steerenberg; L Balemans; E J Ruitenberg
Effective immunotherapy with local low doses of interleukin-2.
In vivo (Athens, Greece) 1991;5(6):561-5.
1991: Jan-Willem Koten; Willem Den Otter
The transition of benign to malignant in epithelial and mesenchymal tumours.
Anticancer research 1991;11(2):567-8.
1990: D J DerKinderen; Jan-Willem Koten; KE Tan; F A Beemer; L K Van Romunde; Willem Den Otter
Parental age in sporadic hereditary retinoblastoma.
American journal of ophthalmology 1990;110(6):605-9.
1990: D J Derkinderen; O J Boxma; Jan-Willem Koten; Willem Den Otter
Stochastic theory of oncogenesis.
Anticancer research 1990;10(2B):497-504.
1990: Willem Den Otter; Jan-Willem Koten; B J Van der Vegt; F A Beemer; O J Boxma; P W De Graaf; D J Derkinderen; FW Hill; J Huber; Wim R Klein
Hereditary cancer and its clinical implications: a view.
Anticancer research 1990;10(2B):489-95.
1990: Willem Den Otter; Jan-Willem Koten; B J Van der Vegt; F A Beemer; O J Boxma; D J Derkinderen; P W De Graaf; J Huber; C J Lips; Paul Roholl
Oncogenesis by mutations in anti-oncogenes: a view.
Anticancer research 1990;10(2B):475-87.
1989: D J DerKinderen; Jan-Willem Koten; L K Van Romunde; N J Nagelkerke; KE Tan; F A Beemer; Willem Den Otter
Early diagnosis of bilateral retinoblastoma reduces death and blindness.
International journal of cancer. Journal international du cancer 1989;44(1):35-9.
1988: D J DerKinderen; Jan-Willem Koten; N J Nagelkerke; KE Tan; F A Beemer; Willem Den Otter
Non-ocular cancer in patients with hereditary retinoblastoma and their relatives.
International journal of cancer. Journal international du cancer 1988;41(4):499-504.
1988: Jan-Willem Koten; D J DerKinderen; Willem Den Otter
Bone sarcomas linked to radiotherapy and chemotherapy in children.
The New England journal of medicine 1988;318(9):581-2.
1988: Willem Den Otter; Jan-Willem Koten; D J DerKinderen; KE Tan
Number of events in tumorigenesis.
Lancet 1988;1(8582):412-3.
1987: Jan-Willem Koten; D J Derkinderen; Willem Den Otter
Pathogenesis of Burkitt's lymphoma in children.
Anticancer research 1987;7(4B):869.
1987: D J Derkinderen; Jan-Willem Koten; R Wolterbeek; F A Beemer; KE Tan; Willem Den Otter
Non-ocular cancer in hereditary retinoblastoma survivors and relatives.
Ophthalmic paediatrics and genetics 1987;8(1):23-5.
1987: W den Otter; Jan-Willem Koten; D J Derkinderen
Carcinogenesis revisited.
Cancer investigation 1987;5(1):69-74.
1986: D J DerKinderen; Jan-Willem Koten; Willem Den Otter; KE Tan; F A Beemer
Retinoblastoma, melanoma, and pancreatic cancer.
Lancet 1986;2(8519):1335-6.
1986: D J DerKinderen; Jan-Willem Koten; F A Beemer; KE Tan; Willem Den Otter
Second nonocular tumors in retinoblastoma survivors: are they radiation-induced?
Ophthalmology 1986;93(8):1124-5.
1986: Willem Den Otter; Jan-Willem Koten; D J Derkinderen
A new model for oncogenesis. From tumour immunology to a mathematical approach of oncogenesis.
Anticancer research 1986;6(3 Pt B):509-14.
1984: H van Loveren; J W de Groot; Jan-Willem Koten; A H Piersma; R A de Weger; Willem Den Otter
A macrophage factor enhancing the systemic anti-tumour effect of T lymphocytes.
Immunobiology 1984;166(2):118-30.